Abstract
Introduction
People with spinal cord injury (SCI) frequently report chronic neuropathic pain that is often refractory to medications [1, 2] . The development of novel pain therapeutic approaches in the field of SCI research is a priority as laid down by a joint position statement of the US Institutes of Medicine and the National Academy of Sciences. Thus, non-pharmacological interventions such as transcranial Direct Current Stimulation (tDCS) can be helpful for reducing neuropathic pain due to SCI.
The number of clinical studies using tDCS has steadily increased in the last years due to its promising clinical results, safety profile, low cost, and relatively easy to use. When applied for sufficient duration, tDCS alters the level of cortical excitability and modulates the firing rate of individual neurons, during and beyond the period of stimulation [3] .
Substantial previous research has shown that anodal tDCS over the primary motor cortex (M1) can induce clinically significant pain relief in chronic pain syndromes [4] [5] [6] that outlast the stimulation period for several weeks [7] [8] [9] , with mild or absent side effects [10] . However, these clinical trials often require large sample sizes, strict inclusion, and exclusion criteria, and require multiple study visits per trial. In fact, it has been shown recently that the response to tDCS in fibromyalgia was achieved in 50% of participants only after 15 sessions [11] . In fact, in our study, in which we tested the effects of M1 tDCS in participants with neuropathic pain following SCI, we showed that a delayed treatment response at 1-week follow-up (after 5 consecutive days of stimulationphase 1) and 4-weeks delayed response after additional 15 days of stimulation (phase 2) [12] . Therefore, the need to have longer periods of treatment together with limitation of transportation of people with SCI pose several potential problems to subject retention, a challenge reflected in trial dropout rates.
Indeed, reasons for dropouts are treatment related; either because the participants were randomized to the active treatment group and experienced adverse side effects, or to the control group and experienced lack of efficacy [13] . Since two meta-analysis have shown significantly higher dropout rates in the placebo arm as compared to the active arm [14] , and adverse effects are associated also with increased dropout from a study, here we are interested in analyzing the data comparing active vs. sham groups.
Therefore, in this article, we present adherence data, such as time for dropout, from one longitudinal clinical trial that was designed to assess the efficacy of repetitive sessions of active vs. sham tDCS on pain relief in participant with chronic neuropathic pain secondary to SCI [12] . Since meta-analysis have shown significantly higher dropout rates in the placebo arm as compared to the active arm [14] , here we are interested in analysing the data in an exploratory manner comparing active vs. sham group.
Moreover, this specific population may have some specific challenges for adherence; for instance, some characteristics such as severity of lesion (that would result in additional transportation difficulties) may be associated with dropout rates. Thus, in this trial, we further explore this issue, by testing the association between several baseline characteristics such as age, depression levels, pain severity, number of days with pain in the last 7 days, walking ability, sleep, work, relationship with others and enjoyment with life with participant´s propensity to dropout from the trial.
Methods
The data presented in this study is the adherence of people with SCI to a long-term clinical trial (SCIMS trial; clinicalTrials.gov Identifier: NCT01599767), which primary objective was to assess the efficacy of tDCS on pain relief. For more details about the effectiveness of tDCS on pain relief please see Thibaut et al. [12] .
Participants
Forty-six participants (10 females) with SCI (based on the American Spinal Injury Association-ASIA-Impairment Scale performed at time of enrollment) with a mean age of 48 (12.88) with moderate to severe sublesional chronic pain (average Visual Analog Scale (VAS) score of 4 or greater) and time (in years) since injury 6(±6.27)), with self-reported pain since injury, were enrolled for the SCIMS trial (inclusion criteria). From those, 33 participants were randomized to receive either active (n = 16) or sham tDCS (n = 17).
The exclusion criteria in the study were: active alcohol or drug dependence; history of bipolar disorder or psychosis; inability to travel to the study site; current use of any of the following anti-epileptic medications or dopaminergic medications known to reduce or inhibit the benefits of tDCS treatment: carbamazepine, oxcarbazepine, phenytoin, ropinirole (Requip), pramipexole (Mirapex), and cabergoline (Dostinex); the following contradictions to tDCS: implanted metal plates in the head, or deep brain stimulator (spinal cord implants, including baclofen pumps, are not a contraindication as cranial currents do not reach the spinal cord). Pregnancy at time of enrollment; and current use of ventilator.
All participants provided written informed consent at enrollment and the study was conducted according to the declaration of Helsinki.
Study design
The complete SCIMS trial involves a total of 21 visits. These visits include, one baseline assessment, 15 daily sessions of tDCS and five follow-up assessments. Of these 21 visits, 4 of the follow-up assessments can be done over the phone, whereas the other 17 visits require the subject to physically travel to the research facility. However, as the duration of this study is quite long (approx. 6 months), the study is divided into two phases, in which the subject is required to consent twice. The first consent is for phase I (visits 1-8) and if participants wish to continue (and continue to meet eligibility), they may consent for phase II (visits 9-21) (Fig. 1) . After a screening assessment to evaluate eligibility for participation, baseline assessments are performed, and participants then undergo five consecutive days of tDCS, with a follow-up at least 1-week post-stimulation. After completion of this first phase, participants have another follow-up visit at least 3 months after the 1-week follow-up. This follow-up visit assesses pain as well as other study measures (such as quality of life and mood). If the subject wishes to continue further into the trial and remains eligible, he/she then consents to the second part of the trial (phase II).
During phase II of the trial, participants received 2-weeks of the tDCS, and are asked to complete three additional follow-up assessment visits (2 weeks, 4 weeks, and 8 weeks after their final tDCS session). These three assessments can be done in person, by mail or by phone. All tDCS sessions were performed using the same parameters as in previous studies e.g., ref. [15] . Each stimulation visit lasts about 30 min (20 min of tDCS) and assessment visits may vary from approximately 1-1.5 h.
All enrolled participants were compensated for their time and transportation costs when necessary.
Statistical analysis
The main objective of the present work was to test if there were differences in term of dropout rate between active and sham tDCS. For that purpose, Kaplan-Meier survival estimates were generated to show the study adherence rates of the two treatment groups (active vs. sham tDCS) throughout the study visits for each respective study. Moreover, the log-rank test was used to evaluate the equality of the survival distributions when comparing the two groups (active and sham tDCS).
The secondary objective was to assess if there were some participant´s characteristics that may be associated with their propensity for dropping out from the study. Thus, point biserial correlations were performed in order to assess the potential relationship between dropout and several In order to assess if there were side effect differences that could explain the dropout rates, Chi-squares tests were performed for each side effect variable in order to assess differences across groups. Fischerʼs exact tests were performed for groups with less than five observations.
Results
The median survival until dropout for both groups was 7 (IQR: 6-19) sessions (that indicated the first follow-up). There were no significant differences between the groups (active vs. sham tDCS) in terms of time to dropout (χ 2 (1) = 0.025, p = 0.88) (Fig. 2) .
We performed an additional analysis to assess if certain baseline variables were associated with dropout. Therefore, we assessed if age, depression levels, pain severity, number of days with pain in the last 7 days, walking ability, sleep, work, relationship with others, and enjoyment with life were associated with dropout. Only the number of days with pain in the last 7 days was moderately associated with dropout, with people experiencing less pain more prone to dropout from the study (rpb = -0.46).
tDCS side effects
Additional analyses were performed to test possible side effects of tDCS on both groups, active vs. sham group. Significant differences were found across groups for side effects of scalp pain (p = 0.036), scalp burning sensation (p = 0.006), tingling (p < 0.001), skin redness (p < 0.001), and sleepiness (p < 0.001) ( Table 1) .
Discussion
This study assessed participants' retention over a longitudinal tDCS clinical trial for pain relief in a cohort of 46 people with SCI.
Overall, the results show that there are no significant differences between active and sham tDCS groups in terms of time to dropout. These results differ from what was previously reported in past trials, namely in meta-analysis that showed that the dropout rates in the placebo arm were significantly higher than the active arm [14] . Moreover, a recent meta-analysis assessing the dropout rate in antidepressant studies using placebo or active comparator, suggested that the dropout rate in the placebo arm was strongly associated with the lack of efficacy [16] , despite no significant difference dropout rate between active (24.3 ± 8.27) vs. placebo (24.0 ± 9.04%) for the trials conducted in the last decade. The reason for the differences here may also be because of better placebo methods for tDCS, which seems to be less guessed as active when compared with drugs [17] . Nonetheless, it is important to highlight that the sample size of the present study was rather small, and as such the lack of a significant difference in terms of adherence to active or sham tDCS needs to be confirmed by larger trials as this may be a type II error.
In the present trial, only 8 (out of 33) participants completed the trial, which translates to a dropout rate of 76%. A recent 16-week long duration trial assessing the effectiveness of physical activity guidelines in patients with SCI, showed a 18% dropout rate [18] . This rate was slightly below the one found in other chronic pain trials, in which dropout rates range from 20 to 50 % [13] . Moreover, usually the reasons for dropouts are treatment related; either because the participants were randomized to the active treatment group and experienced adverse side effects, or to the control group and experienced lack of efficacy [13] . The results from this exploratory study show that tDCS had a delayed pain decrease at 1-week follow-up for phase 1 and only at 4-week follow-up for phase II [12] . This delayed response to intervention may potentially explain the loss to follow-up in this trial, since participants may perceived this intervention as not working as expected or they believed they were receiving sham tDCS.
Another important aspect to consider in this perceived lack of efficacy is the definition of the maximum pain relief that the intervention is able to induce, or simply what do participants perceive as pain relief. A recent study with chronic neuropathic pain following fibromyalgia suggested that 15 sessions may be the median number of sessions required in order to induce a significant clinical effect (i.e., 50% pain reduction) [11] . Thus, it may be possible that five consecutive sessions were not able to induce sufficient pain relief in this population to be perceived as such up to that point. This perceived lack of efficacy could potentially explain the dropout of participants following the first round of tDCS.
Another possibility for this high dropout rate could be the potential side effects that arose from the intervention. This has been already shown extensively in the literature, in which increased dropout rate in drug trials is significantly associated with adverse effect severity [19, 20] . This could certainly be the case in this study, as participants with SCI submitted to verum stimulation reported significant more skin redness, sleepiness, scalp pain, scalp burning sensation, and tingling as compared to those receiving the placebo. However, when these side effects were reported, most of them were of mild severity-which is consistent with previous reports in the literature [21] . Thus, side effects do not seem to have influenced adherence in the present trial. Moreover, the difference in terms of absolute dropout rate between groups is inferior to 15%, which suggests a low risk of intervention induced bias. It has also been suggested that trial design, type of intervention, geographic area, or culture can contribute for participants' dropout rate [14] . Mobility difficulties may also have impacted the adherence of these participants to the clinical trial. In fact, a multicentre trial with people with SCI demonstrated an inverse relationship between mobility and pain scores, i.e., people with moderate to high levels of mobility reported less pain [22] . Moreover, people with chronic pain and SCI have high susceptibility to stress and depression [23, 24] , which can seriously affect their adherence to time demanding clinical trials. All of these factors may increase burden to participants, and thus contribute to study dropout. Indeed, adherence in this specific population may be predicted more by burden related to research procedures (i.e., visits and/or travel) than by efficacy of treatment. For instance, a previous trial showed that repeated administration of onabotulinumtoxinA detrusor injections every 6 months improved their incontinence problems, but despite that, only 20% of patients continued the repeated treatment [25] .
In the present study, there were no differences between active and sham tDCS in terms of participants' propensity to dropout, but there was an overall high dropout rate. Therefore, we performed additional analysis to assess if certain baseline variables, such as age, depression levels, pain severity, number of days with pain in the last 7 days, walking ability, sleep, work, relationship with others and enjoyment with life, were associated with dropout. Results show that only the number of days with pain in the last 7 days was moderately associated with dropout, with people experiencing less pain being more prone to dropout from the study. This is an interesting result, as it seems that pain severity or level of pain seem to affect study adherence. On the other hand, as shown before higher pain at baseline may indicate more refractoriness to tDCS [15] . Future studies should take this in consideration when determining study population, as it seems that people with higher levels of pain are more motivated to travel to the research facility for multiple tDCS sessions.
For those reasons, it is important to offer to these participants, new options such as the possibility of participating in the stimulation and assessment sessions at home with remote assistance from the clinical and research setting. Therefore, the development of home-based protocols can be very useful in order to overcome this difficulty trial compliance [26] .
Another interesting result in this trial is that, participants tend to dropout from the study after the screening assessment, prior to actual study commencement, as loss to follow-up slope is greater at that point (see Fig. 1 ). So, in the absence of perceived early benefits from the intervention, adherence may be suboptimal. Once participants actually start the stimulation, most participants do not dropout until completion of the stimulation sessions. The dropout rates increase again during the follow-up assessment visits. One possibility is that the one that feel greater pain, are also the ones more motivated to be complete the stimulation sessions because of the potential clinical benefits. As soon as therapy ends, then they are less likely to adhere to the assessments that will not be perceived as having any clinical benefit.
This loss to follow-up has been reported in many other clinical trials [27, 28] , and poses serious threats to the validity of the study by potentially introducing bias to the results, as participants that dropout may have distinct characteristics from those that do not dropout [29] . Again, it is not possible to disentangle if this high dropout rate was due to lack of perceived efficacy of the tDCS intervention. If the pain levels were low enough for them to dropout from the study, or even if in low levels of pain there is no actual benefit from the tDCS intervention or in the case there is, the effects are not perceived as beneficial.
It is important to highlight that in the SCIMS trial, participants were given the opportunity to perform follow-up assessments over the phone. Despite that, there was a significant loss to follow-up, starting at 1 month after tDCS has ended. It is possible that the elapsed time between the stimulation and the follow-up assessments negatively impacted participants' motivation to continue in the trial. Moreover, it is possible that the intervention´s perceived lack of efficacy increased over time, as the perceived potential benefits were becoming smaller. Additionally, participants may have felt more motivated to receive the intervention rather than complete the long follow-up assessments (with a 1-hour burden).
This study is one of the first studies testing the effectiveness of tDCS for chronic neuropathic pain in people with SCI with long follow-ups (that showed to be important given our efficacy results please see ref. [12] . And as such, a placebo intervention (i.e., sham tDCS) was chosen as comparator in order to increase the validity of the results, especially due to the 15 sessions timeframe that has been shown to induce a clinical meaningful effect in terms of pain relief. Thus, in this sense, it was important to maintain the comparator across the 15 sessions. If there seem to be no differences in terms of dropout rates due to comparator, the available data suggest that, future longitudinal tDCS clinical trials with participants with SCI, may benefit from changes in the study design. First of all, patients with refractory pain may be more prone to adhere to the study. Second, at early stages of the intervention adherence may be improved by facilitating the commute to the research facility. But if these trials require larger time commitments, a stepped home intervention may be more beneficial (see Fig. 1 ). Additionally, one limitation of this study was that subjects were randomized upon consenting, and that may have produced a minor imbalance in groups prior to the start of stimulation. Therefore, future studies should only perform subject´s randomization subjects immediately before the first stimulation session.
Conclusion and future directions
This work provides insights about the participants' adherence to long-term clinical trials assessing the effect of tDCS for pain relief. Despite the safety profile of tDCS and the absent difference in terms of dropout rate between active and sham tDCS groups, long-term clinical trials remain a challenge for research participants. Specific populations may be more vulnerable for this long-term adherence commitment than others, especially those with lower levels of pain. Special attention must be given to long-term follow-ups, especially those that involve a significant time burden for participants. Trials should be designed in order to include specific strategies that aim to increase compliance in different phases of the clinical trial. These patientdirected strategies to improve compliance may include education about the relevance of the clinical trial and about her/his adherence to all regimens (including assessments). Some recommendations to improve adherence are summarized in Table 2 . Uncertain benefits and potential risks associated with participation can impact compliance. This should be discussed and monitored with participants.
Family and friends centered:
Involving family and friends in the treatment may also have a positive impact on compliance by increasing the social support to the subject. Depending on specific personal characteristics and needs of the participant, family and friends can be involved in order to support the subject during his/her participation.
